Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Update

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 3,033 shares, a growth of 85.7% from the June 30th total of 1,633 shares. Based on an average trading volume of 65,515 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company’s stock are sold short.

Emmaus Life Sciences Stock Performance

EMMA opened at $0.01 on Thursday. The company has a 50-day moving average of $0.01 and a 200-day moving average of $0.01. The company has a market capitalization of $701,900.00, a P/E ratio of -0.08 and a beta of 9.06. Emmaus Life Sciences has a 1-year low of $0.01 and a 1-year high of $0.02.

Emmaus Life Sciences (OTCMKTS:EMMA) last issued its earnings results on Friday, May 15th. The company reported ($0.05) earnings per share (EPS) for the quarter. The firm had revenue of $1.98 million for the quarter.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.